SCHEMBL14903449

SCHEMBL14903449

O=COc1n[nH]c2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARG P13631 1/20 0.50
KDM4E B2RXH2 6/20 0.47
GAA P10253 2/20 0.47
PDPK1 O15530 1/20 0.47
CYP3A4 P08684 1/20 0.47
CNR1 P21554 3/20 0.46
CNR2 P34972 3/20 0.46
CYP1A2 P05177 1/20 0.44
IDO1 P14902 3/20 0.44
ALDH1A1 P00352 2/20 0.44
ALPL P05186 1/20 0.44
HPGD P15428 1/20 0.44
TTK P33981 1/20 0.44
MAPK10 P53779 1/20 0.44
STAT3 P40763 1/20 0.44
HIF1A Q16665 1/20 0.44
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
TP53 P04637 1/20 0.42
YTHDC1 Q96MU7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL460612 0.78 RARG (0.68) RARGKDM4EGAAPDPK1CYP3A4
SCHEMBL28772881 0.76 NOS1 (0.35) PDPK1CNR1CNR2
SCHEMBL22518509 0.76 FADS1 (0.42) RARGGAACYP1A2HPGDMAP2K4
SCHEMBL5820415 0.75 KDM4E (0.53) RARGKDM4EGAAPDPK1CYP3A4
SCHEMBL1966860 0.75 CNR1 (0.59) RARGKDM4EGAAPDPK1CYP3A4
SCHEMBL31134461 0.75 CNR1 (0.59) RARGKDM4EGAAPDPK1CYP3A4
SCHEMBL5360110 0.74 RARG (0.50) RARGKDM4EGAAPDPK1CYP3A4
SCHEMBL5943485 0.73 RARG (0.53) RARGKDM4EGAAPDPK1CYP3A4
SCHEMBL4193104 0.73 RARG (0.53) RARGKDM4EGAAPDPK1CYP3A4
SCHEMBL1563249 0.73 KDM4E (0.50) RARGKDM4EGAAPDPK1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE46943-E1 Radioprotector compounds and methods PETER MACCALLUM CANCER INSTITUTE (AU) 2018-07-10 US disclosed
US-8999993-B2 Radioprotector compounds and methods PETER MACCALLUM CANCER INSTITUTE (AU) 2015-04-07 US disclosed
US-20130109678-A1 RADIOPROTECTOR COMPOUNDS AND METHODS PETER MACCALLUM CANCER INSTITUTE (AU) 2013-05-02 US disclosed
CN-101160128-B Protective agent for retinal neuronal cell comprising indazole derivative as active ingredient UBE INDUSTRIES 2010-08-18 CN disclosed
CN-101160128-A Protective agent for retinal neuronal cell comprising indazole derivative as active ingredient UBE INDUSTRIES (JP) 2008-04-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109678-A1 RADIOPROTECTOR COMPOUNDS AND METHODS NR1H2, NR1H3, NR1I3 RARG 349/4885KDM4E 3680/4885GAA 4803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.